Published in Lancet on August 30, 2003
Interaction Between HIV and Platelets (PLAQUEVIH) | NCT04062825
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet (2008) 12.35
Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ (2008) 8.70
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS (2008) 3.31
Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med (2008) 2.82
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol (2009) 2.51
Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers. HIV Med (2009) 2.48
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (2014) 2.27
Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis (2011) 1.91
Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients. J Acquir Immune Defic Syndr (2007) 1.71
Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies. PLoS Med (2010) 1.65
CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med (2012) 1.54
Outcomes of antiretroviral treatment program in Ethiopia: retention of patients in care is a major challenge and varies across health facilities. BMC Health Serv Res (2011) 1.47
The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. J Int AIDS Soc (2010) 1.45
Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Côte d'Ivoire. J Acquir Immune Defic Syndr (2011) 1.34
Evaluation of PIMA™® point of care technology for CD4 T cell enumeration in Kenya. PLoS One (2013) 1.32
Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). Int J Epidemiol (2013) 1.27
Determinants of early and late mortality among HIV-infected individuals receiving home-based antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr (2011) 1.21
A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256. J Infect Dis (2012) 1.17
CD4+ response and subsequent risk of death among patients on antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr (2009) 1.15
Gender differences in mortality and CD4 count response among virally suppressed HIV-positive patients. J Womens Health (Larchmt) (2013) 1.14
The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients. HIV Clin Trials (2011) 1.04
Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. J Acquir Immune Defic Syndr (2009) 1.04
Adherence to antiretroviral therapy (ART) during the early months of treatment in rural Zambia: influence of demographic characteristics and social surroundings of patients. Ann Clin Microbiol Antimicrob (2012) 0.98
Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. J Acquir Immune Defic Syndr (2011) 0.97
Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in Botswana. PLoS One (2011) 0.94
Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. J Infect Dis (2014) 0.93
Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? AIDS (2008) 0.91
Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challenge. Curr HIV/AIDS Rep (2015) 0.89
Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort. J Int AIDS Soc (2014) 0.89
Sex differences in HIV outcomes in the highly active antiretroviral therapy era: a systematic review. AIDS Res Hum Retroviruses (2014) 0.88
Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study. J Acquir Immune Defic Syndr (2010) 0.88
Factors predicting discordant virological and immunological responses to antiretroviral therapy in HIV-1 clade C infected Zulu/Xhosa in South Africa. PLoS One (2012) 0.88
Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen--ANRS 111 trial. Fundam Clin Pharmacol (2009) 0.87
CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2011) 0.87
The interplay between CD4 cell count, viral load suppression and duration of antiretroviral therapy on mortality in a resource-limited setting. Trop Med Int Health (2013) 0.86
Using mathematical modeling and control to develop structured treatment interruption strategies for HIV infection. Drug Alcohol Depend (2007) 0.86
Specific eradication of HIV-1 from infected cultured cells. AIDS Res Ther (2010) 0.85
Immunologic response to highly active antiretroviral therapy and mortality reduction in a cohort of human immunodeficiency virus-positive persons in Mozambique. Am J Trop Med Hyg (2010) 0.85
Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development. HIV Clin Trials (2012) 0.84
Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies. AIDS (2013) 0.84
Outcomes of second combination antiretroviral therapy regimens among HIV-infected persons in clinical care: a multicenter cohort study. AIDS Res Hum Retroviruses (2012) 0.84
Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μl Despite Effective HAART. PLoS One (2015) 0.83
Kaposi sarcoma-associated herpes virus and response to antiretroviral therapy: a prospective study of HIV-infected adults. J Acquir Immune Defic Syndr (2013) 0.82
Predictive value of CD4 cell count nadir on long-term mortality in HIV-positive patients in Uganda. HIV AIDS (Auckl) (2012) 0.81
HIV protease inhibitors and obesity. Curr Opin Endocrinol Diabetes Obes (2010) 0.81
Causes of Death among AIDS Patients after Introduction of Free Combination Antiretroviral Therapy (cART) in Three Chinese Provinces, 2010-2011. PLoS One (2015) 0.80
Laboratory and clinical predictors of disease progression following initiation of combination therapy in HIV-infected adults in Thailand. PLoS One (2012) 0.80
Baseline immune phenotypes and CD4+ T lymphocyte responses to antiretroviral therapy in younger versus older HIV-infected individuals. J Clin Immunol (2011) 0.80
Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. Clin Infect Dis (2016) 0.79
Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case-Cohort Study. J Acquir Immune Defic Syndr (2015) 0.79
Assessing the performance of a computer-based policy model of HIV and AIDS. PLoS One (2010) 0.79
A stochastic multi-scale model of HIV-1 transmission for decision-making: application to a MSM population. PLoS One (2013) 0.79
Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo). Antimicrob Agents Chemother (2012) 0.78
A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy. J Acquir Immune Defic Syndr (2014) 0.76
Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: results from the TREAT Asia HIV observational database. J Int Assoc Provid AIDS Care (2013) 0.76
HIV-Care Outcome in Saudi Arabia; a Longitudinal Cohort. J AIDS Clin Res (2014) 0.75
Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses. Lancet Public Health (2016) 0.75
Viral load responses to HAART is an independent predictor of a new AIDS event in late stage HIV infected patients: prospective cohort study. J Transl Med (2005) 0.75
Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults. AIDS (2017) 0.75
Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science (2000) 16.04
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet (2008) 12.35
Whole-genome comparison of Mycobacterium tuberculosis clinical and laboratory strains. J Bacteriol (2002) 8.88
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol (1989) 8.32
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet (1998) 7.53
Meta-analysis: principles and procedures. BMJ (1997) 6.87
The Spectrum projection package: improvements in estimating mortality, ART needs, PMTCT impact and uncertainty bounds. Sex Transm Infect (2008) 5.98
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother (1998) 5.64
Risk factors for ischaemic heart disease: the prospective phase of the British Regional Heart Study. J Epidemiol Community Health (1985) 5.53
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet (2000) 5.49
Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis (2005) 5.20
Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med (1998) 5.08
Confounding in epidemiological studies: why "independent" effects may not be all they seem. BMJ (1992) 4.79
Relation of particle dimension to carcinogenicity in amphibole asbestoses and other fibrous minerals. J Natl Cancer Inst (1981) 4.60
Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet (1986) 4.54
Carcinogenicity of fibrous glass: pleural response in the rat in relation to fiber dimension. J Natl Cancer Inst (1977) 4.28
Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet (1989) 4.19
Social class differences in ischaemic heart disease in British men. Lancet (1987) 4.09
Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med (2000) 3.95
Smoking as "independent" risk factor for suicide: illustration of an artifact from observational epidemiology? Lancet (1992) 3.92
Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis (2010) 3.79
Identifying men at high risk of heart attacks: strategy for use in general practice. Br Med J (Clin Res Ed) (1986) 3.76
Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med (2001) 3.74
Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group. AIDS (1999) 3.67
Failure of zidovudine prophylaxis after accidental exposure to HIV-1. N Engl J Med (1990) 3.61
Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest (1988) 3.59
Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet (1999) 3.41
A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature (2001) 3.28
Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J (Clin Res Ed) (1986) 3.27
Associations of wheezing phenotypes in the first 6 years of life with atopy, lung function and airway responsiveness in mid-childhood. Thorax (2008) 3.25
Staphylococcus lugdunensis endocarditis. Lancet (1989) 3.21
Association between CCR5 genotype and the clinical course of HIV-1 infection. Ann Intern Med (1997) 3.08
Distribution and significance of fecal indicator organisms in the Upper Chesapeake Bay. Appl Microbiol (1975) 2.99
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA (2001) 2.95
Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS (2002) 2.90
Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS (1998) 2.90
Clinical significance of small-intestinal microsporidiosis in HIV-1-infected individuals. Lancet (1991) 2.87
Sexual and reproductive life of women informed of their HIV seropositivity: a prospective cohort study in Burkina Faso. J Acquir Immune Defic Syndr (2001) 2.86
What is known about the prevention of congenital toxoplasmosis? Lancet (1990) 2.78
Passive smoking and health: should we believe Philip Morris's "experts"? BMJ (1996) 2.76
Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda. Mother-to-Child HIV-1 Transmission Study Group. Pediatrics (1999) 2.69
Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant (2011) 2.69
Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet (1998) 2.67
Late presentation of HIV infection: a consensus definition. HIV Med (2011) 2.67
Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS (1997) 2.59
A scoring system to identify men at high risk of a heart attack. Health Trends (1987) 2.58
Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med (1992) 2.57
Chronic Q fever. Ninety-two cases from France, including 27 cases without endocarditis. Arch Intern Med (1993) 2.57
Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. AIDS in Europe Study Group. JAMA (1994) 2.56
Evaluation of the Directigen FluA+B test for rapid diagnosis of influenza virus type A and B infections. J Clin Microbiol (2002) 2.56
Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine. Antimicrob Agents Chemother (1985) 2.55
Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team. N Engl J Med (1993) 2.55
Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies. J Infect Dis (2006) 2.54
Diagnosis of intestinal and disseminated microsporidial infections in patients with HIV by a new rapid fluorescence technique. J Clin Pathol (1993) 2.52
Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol (2009) 2.51
Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis (2001) 2.50
Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers. HIV Med (2009) 2.48
Concentrations of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart disease. BMJ (1989) 2.47
Comparison of multilocus sequence typing and pulsed-field gel electrophoresis as tools for typing Staphylococcus aureus isolates in a microepidemiological setting. J Clin Microbiol (2002) 2.45
Risk factors for stroke in middle aged British men. BMJ (1991) 2.44
The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med (2006) 2.38
Incidence and consequences of pregnancy in women with known duration of HIV infection. Italian Seroconversion Study Group. Arch Intern Med (1998) 2.38
Biphasic rate of CD4+ cell count decline during progression to AIDS correlates with HIV-1 phenotype. AIDS (1992) 2.35
Operational issues in preventing mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire, 1998-99. Bull World Health Organ (2001) 2.33
Risk factors and prevalence of HIV antibodies in homosexual men in the Netherlands. Am J Epidemiol (1987) 2.32
A Bayesian approach to parameter estimation in HIV dynamical models. Stat Med (2002) 2.30
Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med (2003) 2.30
Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis. Clin Exp Immunol (1992) 2.27
Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis (2004) 2.26
Vitamin A supplementation for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev (2005) 2.26
Diagnosed and undiagnosed HIV-infected populations in Europe. HIV Med (2008) 2.26
Effect of standard breakfast on drug absorption and multiple-dose pharmacokinetics of ciprofloxacin. Antimicrob Agents Chemother (1985) 2.25
Inflation in epidemiology: "the proof and measurement of association between two things" revisited. BMJ (1996) 2.24
Epidemiological, social, diagnostic and economic evaluation of population screening for genital chlamydial infection. Health Technol Assess (2007) 2.23
Prevalence of cutaneous disorders in a population of HIV-infected patients. Southwestern France, 1996. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Arch Dermatol (1998) 2.22
Factors affecting survival in patients with the acquired immunodeficiency syndrome. AIDS (1996) 2.22
A prospective study of criteria for the diagnosis of toxoplasmic encephalitis in 186 AIDS patients. The BIOTOXO Study Group. AIDS (1997) 2.21
Monitoring selective components of primary health care: methodology and community assessment of vaccination, diarrhoea, and malaria practices in Conakry, Guinea. ACSI-CCCD team. Bull World Health Organ (1989) 2.20
Survival of herpes simplex virus in water specimens collected from hot tubs in spa facilities and on plastic surfaces. JAMA (1983) 2.20
Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen. AIDS (1998) 2.19
Infective and anti-infective properties of breastmilk from HIV-1-infected women. Lancet (1993) 2.18
Neural correlates of first-person perspective as one constituent of human self-consciousness. J Cogn Neurosci (2004) 2.16
Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis (2007) 2.16